Author

B. Daley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

C. Rao· 1 shared D. Chatterjee· 1 shared D. H. Huisman· 1 shared H. M. Vieira· 1 shared J. M. Hughes· 1 shared J. W. Askew· 1 shared K. Cox· 1 shared K. W. Fisher· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

C. Rao

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

B. Daley, H. M. Vieira, C. Rao, J. M. Hughes, Z. M. Beckley, D. H. Huisman, D. Chatterjee, N. E. Sealover, K. Cox, J. W. Askew, R. A. Svoboda, K. W. Fisher, R. E. Lewis, R. L. Kortum

This study shows that targeting SOS1 or KSR1 enhances MEK inhibitor efficacy and prevents resistance in KRAS-mutated cancers, depending on specific KRAS and co-mutation status.

bioRxiv · Dec 6, 2022Cancer Biology